Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

Condition:   Tick-Borne Encephalitis Interventions:   Biological: TBE vaccine 0.5 mL;   Biological: TBE vaccine 0.25 mL Sponsor:   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials